Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RAD001 versus placebo in advanced pancreatic neuroendocrine tumor
NL-OMON30904Phase 3Active, not recruiting
- Sponsor
- Novartis
- Start
- Jul 2007
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in islet cell tumor comparing Everolimus plus best supportive care with Placebo plus best supportive care (2 arms). Primary endpoint: Progression-free survival. Started Jul 2007; status: active, not recruiting.
02
Drugs
everolimus
03
Conditions
islet cell tumor
Beyond the preview
Go deeper on NL-OMON30904.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON30904.